Marco Boorsma, Forbion
With a roster of gene therapy vets, Forbion makes a bet on 'relatively empty space' of vectorized antibodies
The future waves of gene therapy could look quite different from the gene replacement offerings currently on the market, Forbion reckons.
It’s the key idea …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
